Abstract
Candida albicans, a dimorphic opportunistic fungal pathogen, can cause a wide range of diseases in humans. Its ability to switch from commensal to pathogenic form is governed by several virulence attributes. The major feature which leads to pathogenicity is its ability to form biofilm. Biofilm formation is a highly regulated multistep process; there are several clinical implications associated with biofilm formation, as sessile cells exhibit high level of resistances against most of the antifungals, and it also protects the cells from harsh hostile environments. The implantable medical devices like catheter support biofilm mode of development by Candida which negatively impacts the health of immunocompromised individuals by causing recurrent infections. This review highlights the mechanism of Candida albicans biofilm formation and its clinical consequences, as well as currently available drugs against biofilm and alternative to drug therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Achkar JM, Fries BC (2010) Candida infections of the genitourinary tract. Clin Microbiol Rev 23(2):253–273
Adair CG, Gorman SP, Feron BM et al (1999) Implications of endotracheal tube biofilm ventilator-associated pneumonia. Intensive Care Med 25:1072–1076
Alem MAS, Oteef MDY, Flowers TH, Douglas LJ (2006) Production of tyrosol by Candida albicans biofilms and its role in quorum sensing and biofilm development. Eukaryot Cell 5(10):1770–1779
Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. Semin Immunol 20(2):86–100
Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH et al (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin Infect Dis 54(8):1110–1122
Calderone RA (2002) Introduction and historical perspectives. In: Calderone RA (ed) Candida and Candidiasis. ASM Press, Washington, DC, pp 3–13
Carratalà J (2002) The antibiotic-lock technique for therapy of ‘highly needed’ infected catheters. Clin Microbiol Infect 8(5):282–289
Cauda R (2009) Candidaemia in patients with an inserted medical device. Drugs 69(Suppl 1):33–38
Chander J (2009) Textbook of medical mycology, 2nd edn. Mehta Publisher, New Delhi
Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183(18):5385–5394
Contreras-Garcia A, Bucioa E, Brackmanc G, Coenyec T, Concheirob A, Alvarez-Lorenzob C (2011) Biofilm inhibition and drug-eluting properties of novel DMAEMA-modified polyethylene and silicone rubber surfaces. Biofouling 27(2):123–135
Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM (1995) Microbial biofilms. Annu Rev Microbiol 49:711–745
Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284(5418):1318–1322
Crump JA, Collignon PJ (2000) Intravascular catheter-associated infections. Eur J Clin Microbiol Infect Dis 19:1–8
Dahham SS, Ali MN, Tabassum H, khan M (2010) Studies on antibacterial and antifungal activity of pomegranate (Punica granatum L.). Am Eurasian J Agric Environ Sci 9(3):273–281
Darouiche RO (2001) Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 33:1567–1572
de Groot PWJ, Bader O, de Boer AD, Weig M, Chauhan N (2013) Adhesins in human fungal pathogens: glue with plenty of stick. Eukaryot Cell 12:470–481. https://doi.org/10.1128/EC.00364-12
Donlan RM (2002) Biofilms: microbial life on surfaces. Emerg Infect Dis 8(9):881–890
Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15(2):167–193
Douglas LJ (2003) Candida biofilms and their role in infection. Trends Microbiol 11(1):30–36
Fanning S, Mitchell AP (2012) Fungal biofilms. PLoS Pathog 8(4):e1002585
Finkel JS, Mitchell AP (2011) Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9(2):109–118
Flemming H, Wingender J (2010) The biofilm matrix. Nat Rev Microbiol 8:623–633. https://doi.org/10.1038/nrmicro2415
Goldmann DA, Pier GB (1993) Pathogenesis of infections related to intravascular catheterization. Clin Microbiol Rev 6:176–192
Hawser SP, Douglas LJ (1994) Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 62(3):915–921
Hogan DA, Vik A, Kolter R (2004) A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 54(5):1212–1223
Jackson BE, Wilhelmus KR, Mitchell BM (2007) Genetically regulated filamentation contributes to Candida albicans virulence during corneal infection. Microb Pathog 42(2–3):88–93
Karlsson AJ, Flessner RM, Gellman SH, Lynn DM, Palecek SP (2010) Polyelectrolytemultilayers fabricated from antifungal β-peptides: design of surfaces that exhibit antifungal activity against Candida albicans. Biomacromolecules 11(9):2321–2328
Kojic EM, Darouiche RO (2004) Candida infections of medical devices. Clin Microbiol Rev 17(2):255–267
Maki DG, Tambyah PA (2001) Engineering out the risk of infection with urinary catheters. Emerg Infect Dis 7:1–6
Mermel LA, Farr BM, Sherertz RJ, Raad II, O’Grady N, Harris JS, Craven DE (2001) Guidelines for the management of intravascular catheter-related infections. Infect Control Hosp Epidemiol 22:222–242
Naglik JR, Moyes DL, Wachtler B, Hube B (2011) Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect 13(12–13):963–976
Nobile CJ, Andes DR, Nett JE, Smith FJ, Yue F, Phan QT et al (2006) Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog 2:e63. https://doi.org/10.1371/journal.ppat.0020063
Nobile CJ, Nett JE, Hernday AD, Homann OR, Deneault JS et al (2009) Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol 7:e1000133
Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM et al (2012) A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148:126–138
Park SJ, Han KH, Park JY, Choi SJ, Lee KH (2014) Influence of bacterial presence on biofilm formation of Candida albicans. Yonsei Med J 55(2):449–458
Ramage G, Lopez-Ribot JL (2005) Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med 118:71–79
Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL (2002) The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 214:95–100
Redding S, Bhatt B, Rawls HR, Siegel G, Scott K, Lopez-Ribot J (2009) Inhibition of Candida albicans biofilm formation on denture material. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107(5):669–672
Rosenbach A, Dignard D, Pierce JV, Whiteway M, Kumamoto CA (2010) Adaptations of Candida albicans for growth in the mammalian intestinal tract. Eukaryot Cell 9(7):1075–1086
Schweizer A, Rupp S, Taylor BN, Rollinghoff M, Schroppel K (2000) The TEA/ATTS transcription factor CaTec1p regulates hyphal development and virulence in Candida albicans. Mol Microbiol 38:435–445
Seddiki SM, Boucherit-Otmani Z, Boucherit K, Badsi-Amir S, Taleb M, Kunkel D (2013) Assessment of the types of catheter infectivity caused by Candida species and their biofilm formation: first study in an intensive care unit in Algeria. Int J Gen Med 6:1–7
Soliman S, Alnajdy D, El-Keblawy AA, Mosa KA, Khoder G, Noreddin AM (2017) Plants’ natural products as alternative promising anti-Candida drugs. Pharmacogn Rev 11(22):104–122
Teughels W, Van Assche N, Sliepen I, Quirynen M (2006) Effect of material characteristics and/or surface topography on biofilm development. Clin Oral Implants Res 17(Suppl 2):68–81
Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, Köhler JR et al (2010) Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 6(3):e1000828
Valle J, Da Re S, Henry M, Fontaine T, Balestrino D, Latour-Lambert P et al (2006) Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide. Proc Natl Acad Sci U S A 103(33):12558–12563
Verstrepen KJ, Klis FM (2006) Flocculation, adhesion and biofilm formation in yeasts. Mol Microbiol 60:5–15. https://doi.org/10.1111/j.1365-2958.2006.05072.x
Wu TG, Mitchell BM, Carothers TS et al (2003) Molecular analysis of the pediatric ocular surface for fungi. Curr Eye Res 26(1):33–36
Zarnowski R, Westler WM, Lacmbouh GA, Marita JM, Bothe JR, Bernhardt J et al (2014) Novel entries in a fungal biofilm matrix encyclopedia. MBio 5:e1333–e1314. https://doi.org/10.1128/mBio.01333-14
Acknowledgements
The author gratefully acknowledges the University Grant Commission, Government of India, for awarding Junior and Senior Research Fellowship.
Conflict of Interest
The author has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pathak, P. (2019). Candida albicans Biofilm: Risks, Complications and Preventive Strategies. In: Bramhachari, P. (eds) Implication of Quorum Sensing and Biofilm Formation in Medicine, Agriculture and Food Industry . Springer, Singapore. https://doi.org/10.1007/978-981-32-9409-7_9
Download citation
DOI: https://doi.org/10.1007/978-981-32-9409-7_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9408-0
Online ISBN: 978-981-32-9409-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)